LSG

Contract Manufacturing

EMCM has the capability and 
expertise to produce Liquids, 
Suspensions
and Gels from small
to large scale with a fully automatic 
closed dosing system to provide a
customer specific bulk product.

Tissues

Design & Development

The Tissues business
segment of EMCM is active
in the processing of tissue
components such as bones,
soft tissues, cells and skin
of
human as well as of animal origin. 

Products

EMCM focuses on
orthopaedic biomaterials,
such as bone cements &
cement restrictors, and also
on human bone allografts,
tissue constructs and its
derivatives.

Products

EMCM focuses on
orthopaedic biomaterials,
such as bone cements &
cement restrictors, and also
on human bone allografts,
tissue constructs and its
derivatives.

Technologies

EMCM hosts a variety of
in-house technologies,
retains highly professional
key personnel, provides
flexibility in operations and
sustains a well-equipped
cleanroom facility.

Technologies

EMCM hosts a variety of
in-house technologies,
retains highly professional
key personnel, provides
flexibility in operations and
sustains a well-equipped
cleanroom facility.

Quality

EMCM is a GMP licenced
establishment and has been
successfully inspected by the
USFDA, ANVISA and other
European authorities for
providing products to the
global markets.

Events

October 4, 2016

CPhl 2016 October 2016, Spain

October 1-3, 2014

Eurospine 2014, Lyon France

October 1-3, 2014

EATB 2014, Lund Sweden

September 11-13, 2014

EBJIS 2014, Utrecht The Netherlands

More Events

News

October 6, 2015

Join us at CPhI 2015

We are excited about exhibiting at CPhI this year from 13 to 15 October (stand 1A36)

August 28, 2015

EMCM contributes to renal cancer treatment through VCC Medical NV partnership

EMCM recently renewed its partnership with VCC Medical NV to support the production of Reniale - a personalised treatment for renal cancer.

August 6, 2015

Cleanroom facilities upgraded to further improve environmental control

We have completed a series of upgrades, which improved the environmental control within our production facilities.

April 29, 2015

Adcon®Gel registration renewed following KFDA inspection

EMCM – a Leader Biomedical Group company - is proud to announce that our Adcon®Gel registration has been renewed

March 20, 2015

See you in Vegas for the AAOS 2015 Annual Meeting

We are proud to be exhibiting at the AAOS 2015 Annual Meeting

March 3, 2015

EMCM/Leader Biomedical launches DBM

Leader Biomedical Group is pleased to announce the launch of its own line of Demineralised Bone Matrix (DBM)

February 25, 2015

Let's connect at IDS 2015

10-14 March 2015

January 20, 2015

Let's connect at the 11th Middle East Orthopaedics conference

EMCM will be attending the 11th Middle East Orthpaedics conference in Dubai in the United Arab Emirates on 26 and 27 January.

January 6, 2015

New corporate strategy bears first fruit

The corporate strategy of EMCM’s parent company, Leader Biomedical, continues to deliver results, establishing new subsidiaries and global partnerships.

November 12, 2014

EMCM installs fully automated inspection machine for ampoules and vials

Extending its focus strategy, EMCM has made an important step in the further optimisation of their ampoule and vial filling processes.

November 4, 2014

EMCM & UK customer ally for Nutraceutical liquid manufacturing

EMCM is starting a cooperation with a new customer, for a new production process for manufacturing, filling and final packaging of an oral solution.

September 30, 2014

Allograft study recognised at EBJIS, Utrecht, the Netherlands

Dr. D. Link (EMCM) received the award for ‘Best Basic Science Study' , study on osteoconductive properties of cancellous bone graft loaded with antibiotics

September 9, 2014

GMP certified Reniale® production at EMCM

The Dutch Healthcare Inspectorate (IGZ) and Farmatec/CIBG granted EMCM the respective GMP certification

August 8, 2014

CritiTech and European Medical Contract Manufacturing announce collaboration to develop API-coated tissue grafts

CritiTech has entered into a collaboration with EMCM to develop tissue grafts coated with a variety of drugs

August 4, 2014

EMCM B.V. announces future strategic direction

Subsequent to its recent acquisition by a Private Equity, EMCM B.V. today announced the formation of its corporate headquarters and

July 21, 2014

EMCM to be issued Import License for human allografts

EMCM is glad to announce a successful audit by the Dutch Healthcare Inspectorate (IGZ), focusing on the human tissue procurement and processing.

June 11, 2014

Issues in Bone Infection, Biofilm and Bone Defect

Bone infection is known to be one of the major problems in orthopaedic surgery.

February 25, 2014

EMCM acquired by Private Equity firm

European Medical Contract Manufacturing B.V. (EMCM) today announces its acquisition by a British Virgin Island-based Private Equity Company for a price of EUR 18Mn. The transfer of ownership and control is to be completed in April 2014.

September 6, 2013

EMCM an Institutional Member of EATB

EMCM is proud to be an Institutional Member of the European Association of Tissue Banks.

July 3, 2013

EMCM announces strategic partnership with Alamo Tissue Service, San Antonio, TX

European Medical Contract Manufacturing (EMCM) has today announced the closing of a strategic collaboration with Alamo Tissue Service (ATS) in the field of development and manufacturing of human grafts and xenografts using proprietary super critical Carbon Dioxide (scCO2) techniques.

November 13, 2012

NovaSterilis Announces EMCM as Strategic Partner for Supercritical CO2 Sterilisation in Europe and Parts of Asia

NovaSterilis Inc., a leader in the development and commercialisation of supercritical carbon dioxide (scCO2) technology announces the addition of European Medical Contract Manufacturing (EMCM) as a licensee of supercritical CO2 sterilisation and NovaSterilis’ exclusive agent for supercritical CO2 technology and equipment in specified territories.

June 19, 2012

CSR - Osteomyelitis in Uganda

aap Implantate AG, the parent company of EMCM B.V., engage in CSR activities to overcome Osteomyelitis in Uganda by providing PerOssal®, a premium aap product, in the nation at no cost. PerOssal® is a newly developed synthetic bone replacement material with two outstanding properties.

June 5, 2012

Collagen Purification @ EMCM

As part of the PIDON consortium Novio Tissue, EMCM has successfully developed a production process for insoluble highly purified type 1 collagen, derived from bovine tendons . This development further enhances the strategic position of EMCM as a developer and manufacturer of collagen based biomaterials for the healthcare industry.

March 26, 2012

Stichting Sanquin Bloedvoorziening & EMCM B.V. have entered into a strategic alliance

Stichting Sanquin Bloedvoorziening & EMCM B.V. have entered into a strategic alliance in the area of Tissue Processing, thus offering Dutch hospitals access to clean & sterile hygienically processed bone tissue processed under super critical gas technology (SCC02), in a quest to redefine orthopedic and cranial surgical procedures in the Netherlands.

September 15, 2011

EMCM successfully clears US-FDA Inspection

Medical Contract Manufacturing (EMCM) has successfully cleared a 4 day US-FDA QSIT audit on 15th September.

August 2, 2011

Interview with Ms. Valster and Mr. Babychan for the European Business Journal

Supporting Opportunities in medical manufacturing

November 15, 2010

EMCM profiteert van kennis in de regio, publicatie in Management Team

Innovatie, van idee tot succesvolle introductie.

News archive
Top